Search for content, post, videos

Category

Business

sean-bohen
0 COMMENT
10 Views
AstraZeneca’s Tagrisso approved in China

The China Food and Drug Administration has granted marketing authorisation for Tagrisso, 40 mg and 80mg once-daily oral tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer whose disease has progressed on or after EGFR tyrosine kinase inhibitor…

karolinska-institutet-science-park
0 COMMENT
47 Views
Aprea enters research collaboration

Aprea Therapeutics announces a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246. The goal of the collaboration is to evaluate and characterize preclinical efficacy of APR-246 in combination with multiple other anti-cancer agents and across multiple tumor types.…

0 COMMENT
34 Views
Targovax moves share listing to Oslo Børs

Targovax announces that its shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. The company was previously listed on Oslo Axess, a regulated and licensed market under the auspices of the Oslo Stock Exchange. “This move marks another exciting step for Targovax. Being part of…

recipharm
0 COMMENT
33 Views
Recipharm manufactures to the Japanese market

Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan. Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden will…

mark_mallon
0 COMMENT
12 Views
AstraZeneca & Circassia enter strategic collaboration

AstraZeneca has entered a strategic collaboration with Circassia Pharmaceuticals for the development and commercialisation of Tudorza and Duaklir in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD). Tudorza was approved and launched in the US in 2012. Duaklir is expected…

solbu
0 COMMENT
20 Views
The new Teva grows stronger – in Norway

In August last year Teva completed its acquisition of Actavis Generics and the new Teva in Norway will be among the 15 largest companies in the country. The new company will be named Teva and will be located at Teva’s facilities in Hagaløkkveien in Asker. Employees from Actavis moved in…

bonesupport
0 COMMENT
10 Views
Bonesupport extends US distribution agreement

BONESUPPORT has extended the term of its U.S. distribution agreement with Zimmer Biomet, where Zimmer will continue to have exclusive rights for BONESUPPORT’s cerament bone void filler product line for Orthopedics, Trauma and Foot and Ankle indications in the United States. “We are extremely pleased to extend our distribution agreement…

idogen
0 COMMENT
10 Views
Idogen strengthens its position in the US

Idogen announces that the United States Patent & Trademark Office has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application. The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s…

jallal
0 COMMENT
3 Views
MedImmune forms development alliance with Sanofi Pasteur

Medimmune and Sanofi Pasteur have announced an agreement to develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV,) jointly. MEDI8897 is currently in a Phase IIb clinical trial in pre-term infants who are ineligible for Synagis, the…

recipharm
0 COMMENT
7 Views
Recipharm’s latest investment

Twenty years after its founding, Recipharm has established itself as a global life science firm with a solid base in its home country, Sweden and has become an example of a successful Nordic CDMO company. The firm is now setting out to strengthen its Swedish operations further with a new…

dignitana-cooling-cap
0 COMMENT
3 Views
Nine new installations in US for DigniCap

Dignitana announces that the DigniCap scalp cooling system, which was cleared in December 2015 by the FDA to reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will soon be available in nine additional medical centers across the United States including the four locations of University of…

signing-agreement
0 COMMENT
2 Views
Vironova signs agreement with the FDA

Vironova signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS). In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body. Vironova…